secwatch.observer — SEC 8-K summary
======================================

Issuer:     SWK Holdings Corp (SWKHL)
CIK:        0001089907
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001552781-24-000494
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SWK Holdings Q2 2024 revenue up 21% to $11.5M; GAAP net income $4.4M vs $3.9M YoY
--------------------------------------------------------------------------------

- Finance receivables segment revenue rose 15.3% to $10.7M; adjusted non-GAAP net income fell to $6.5M from $7.6M YoY.
- Provision for credit losses totaled $4.1M driven by impairments on Trio ($2.1M) and Exeevo ($2.2M) loans.
- Non-accrual finance receivables were $22.4M at June 30, 2024; portfolio includes Flowonix, Exeevo, Ideal Implant, Best ABT, Trio.
- Post-quarter closed up to $11M royalty financing with Relief Therapeutics; $5.8M advanced at close.
- Non-GAAP tangible financing book value per share grew 6.4% to $20.17; GAAP book value per share $22.75.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1089907/000155278124000494/0001552781-24-000494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1089907/000155278124000494/e24351_swkh-8k.htm
  HTML page:      https://secwatch.observer/filing/0001552781-24-000494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer